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T he T cells of the immune system can kill cells that express a molecule known as an antigen, if the antigen is specifically recognized by a T-cell receptor protein (TCR). T cells can be removed from the body and genetically modified in vitro to insert the sequence encoding an engineered TCR known as a chimaeric antigen receptor (CAR). A CAR can be designed to recognize an antigen expressed in a cancer cell, such as the CD19 antigen. These genetically engineered cells, called CAR T cells, are returned to the patient's body, and this approach has successfully treated some cancers 1 . As they report on page 113, Eyquem et al. 2 have developed an approach to integrating DNA sequences encoding CARs into T cells that offers several advantages over the strategies currently used.
During T-cell development, T cells rearrange gene sequences that encode the TCR so that each T cell expresses a unique TCR that binds a specific antigen. T cells with TCRs that have a high affinity for antigens expressed by the body's own cells (self antigens) are destroyed to avoid autoimmunity. Attacks on tumours by T cells are usually weak because tumours express self antigens. Most current approaches to making CAR T cells insert the CAR-encoding gene into T cells without disrupting the resident TCR gene. This means that the patients' own T cells have to be used to avoid the risk of rejection or graft-versushost disease when the T cells are transplanted back into the body. However, a recent study has explored disrupting the resident TCR α-chain constant region (TRAC) sequence when creating CAR T cells, thereby disabling the TCR and enabling a patient to be treated with CAR T cells made from another person's cells 3 
.
To create a consistent way to introduce CAR sequences into T cells, Eyquem and colleagues decided to integrate a CAR sequence directly into the TRAC. A direct-insertion strategy to genetically modify DNA sequences in human T cells has been used to target the CCR5 gene using zinc-finger nuclease enzymes 4, 5 , and RNA-based nuclease enzymes have integrated CAR sequences into the CCR5 locus 6 . The direct-insertion strategy for CAR sequences chosen by Eyquem and co-workers used CRISPR-Cas9 gene-editing tools. The authors introduced RNA encoding the DNAcleaving nuclease enzyme Cas9 into T cells along with an RNA 'guide' sequence that targets the TRAC sequence. The Cas9 protein used the RNA guide sequence to create a targeted double-stranded break in the TRAC DNA sequence. A viral vector with a CAR sequence flanked by sequences homologous to the TRAC sequence was introduced into the T cells. The double-stranded break in the TRAC sequence was repaired using the viral vector sequence as a template, resulting in the original TRAC sequences being replaced by the introduced CAR sequences (Fig. 1) .
In genetic engineering approaches, viral promoter sequences can be used to drive gene expression, which can result in high expression. However, expression often drops off over time. Constitutively active promoters offer another way to drive gene expression. Both types of promoter approach have been shown to drive constitutive CAR signalling in T cells 7, 8 , and this can affect the ability of CAR T cells to control tumours. Constitutive T-cell activation might cause T-cell exhaustion, a dysfunctional T-cell state characterized by the inability to exert antitumour effects and the expression of some inhibitory receptor proteins such as PD-1 (ref. 9) . Constitutive signalling might also result in toxicity because of To test how the pattern of CAR expression affects the effectiveness of the T-cell response, Eyquem and colleagues tested four promoter sequences that drive gene expression. The promoters tested were of different strengths, and the authors also tested promoterless CARs integrated into two different gene loci. Their results demonstrate that integration of a promoterless CAR into the TRAC sequence results in a more consistent baseline level of CAR expression, more regulated expression of the CAR at both the transcriptional and protein level, and more effective antitumour responses in mouse models of leukaemia. This was probably because CAR expression driven by the natural TCR promoter avoids constitutive CAR signalling and the CAR expression is coupled to T-cell activation. It remains to be determined whether this CAR-expression approach results in any improvement in the toxicity profile of CAR T cells, which remains a substantial challenge in the clinic.
In more than 500 patient-years of follow-up from genetically modified T-cell treatment, the random integration of viral vectors has not been implicated as the cause of any cancers 10 . However, the risk is present, and the long-term follow-up required in these studies is expensive; perhaps both could be eliminated if there were sufficient confidence in the rarity of offtarget effects in the method used. If Eyquem and co-worker's approach is used, CRISPRCas9 off-target gene edits in CAR T cells are likely to occur only at defined regions of the genome, and the risks from such edits should be easier to assess, given that the technologies for identifying the frequency and location of such off-target edits are improving rapidly 11 . The use of CAR T cells has resulted in some successful clinical outcomes, especially in CD19-expressing B-cell acute leukaemias 1 . However, there is room for improvement in the treatment of some CD19-expressing lymphoma cancers and of solid tumours, for which CAR T-cell therapy has not been very effective. Treatment of some of these conditions might be hindered by T-cell exhaustion. Other researchers have combined CAR T cells with gene editing to remove exhaustion-associated inhibitory pathway proteins 12 . In the future, it might be interesting to compare how different combinations of gene knockouts (such as targeting T-cell-exhaustion pathways) and CAR integration might affect T-cell function. Such analysis could enhance our understanding of T-cell biology in a way that also illuminates therapeutic uses.
Eyquem and colleagues' strategy provides three important improvements for T-cellbased therapies. First, CAR T cells generated using their method made more-effective antitumour responses than CAR T cells generated using current standard techniques. Second, the targeted nature of their CAR integration might prove safer than random integration, which carries the potential risk of generating a harmful mutation. Third, this approach might enable off-the-shelf CAR T cells to be made that need not come from a patient's own T cells. This would enable easier and cheaper manufacture of CAR T cells, an outcome that would be particularly helpful for the treatment of severely immunocompromised patients. ■ Marcela V. Maus 
